Recent Updates
Recently added Catalysts

NNC9733-0001

Phase 1

Healthy Volunteer | Small molecule | Metabolic |Novo Nordisk A/S|Last Updated: Dec 8, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindCONTROLLEDBiomarker
Total Trials1
Total Enrollment72
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07270731A Research Study of a New Medicine, NNC9733-0001, in Healthy Participants and Participants With Type 2 DiabetesPHASE1 RECRUITING 72 — — Nov 25, 2025Nov 12, 2027Dec 8, 20251 Germany
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of treatment emergent adverse events (TEAEs)
From dosing (day 1) until end of study (EOS) visit (week 36)

Measured as number of events

Number of hypoglycaemic events
From dosing (day 1) until end of study (EOS) visit (week 36)

Measured as number of events

Secondary Endpoints
AUC0-last: The area under the NNC9733-0001 plasma concentration-time curve from time zero to last measurable concentration after a single dose
From dosing (day 1) to 48 hours after dosing
Cmax: The maximum concentration of NNC9733-0001 in plasma
From dosing (day 1) to 48 hours after dosing
tmax: The time from dose administration to maximum plasma concentration of NNC9733-0001
From dosing (day 1) to 48 hours after dosing
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
NNC9733-0001EXPERIMENTALParticipants will be administered a single dose of NNC9733-0001 in a dose escalated manner.
PlaceboEXPERIMENTALParticipants will be administered a single dose of matching NNC9733-0001 placebo in a dose escalated manner.
Interventions
NameTypeDescription
NNC9733-0001DRUGAdministered a single dose of NNC9733-0001.
PlaceboDRUGAdministered a single dose of matching NNC9733-0001 placebo.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 64 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: All participants * Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine eligibility for the study. * Male, or female of nonchildbearing potential ...

Countries:Germany
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT07270731primaryCompletionDate: changed
LOWMay 24, 2026NCT07270731studyFirstPostDate: changed